Lodoxamide

Lodoxamide
Names
	Preferred IUPAC name N,N′-(2-Chloro-5-cyano-1,3-phenylene)dioxamic acid
Identifiers
CAS Number	53882-12-5 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1201266 ;
ChemSpider	40543 ;
DrugBank	DB06794;
PubChem CID	44564;
UNII	SPU695OD73 ;
CompTox Dashboard (EPA)	DTXSID9057767 ;
	InChI InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21) Key: RVGLGHVJXCETIO-UHFFFAOYSA-N ; InChI=1/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21) Key: RVGLGHVJXCETIO-UHFFFAOYAZ;
	SMILES N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1;
Properties
Chemical formula	C11H6ClN3O6
Molar mass	311.63 g·mol−1
Pharmacology
ATC code	S01GX05 (WHO)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer.^[1] In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.^[2]

References

↑ Avunduk, A. M.; Avunduk, M. C.; Kapicioglu, Z.; Akyol, N.; Tavli, L. (2000). "Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis". Ophthalmology. 107 (7): 1333–1337. doi:10.1016/S0161-6420(00)00089-0. PMID 10890862.
↑ MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L; Markwick, R; Charlton, SJ; Milligan, G (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35". Molecular Pharmacology. 85 (1): 91–104. doi:10.1124/mol.113.089482. ISSN 0026-895X. PMC 3868900. PMID 24113750.